PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
44.99%
R&D growth while AVXL reduces spending. John Neff would investigate strategic advantage.
-4.08%
G&A reduction while AVXL shows 19.92% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
80.19%
Other expenses change of 80.19% while AVXL maintains costs. Bruce Berkowitz would investigate efficiency.
21.99%
Operating expenses growth while AVXL reduces costs. John Neff would investigate differences.
21.99%
Total costs growth while AVXL reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
80.19%
D&A change of 80.19% while AVXL maintains D&A. Bruce Berkowitz would investigate efficiency.
32.89%
EBITDA growth exceeding 1.5x AVXL's 1.12%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-21.99%
Operating income decline while AVXL shows 1.12% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
198.65%
Other expenses growth above 1.5x AVXL's 98.95%. Michael Burry would check for concerning trends.
32.68%
Pre-tax income growth 1.25-1.5x AVXL's 26.50%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.68%
Net income growth 1.25-1.5x AVXL's 26.17%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
32.51%
EPS growth 1.25-1.5x AVXL's 25.00%. Bruce Berkowitz would examine sustainability.
32.51%
Diluted EPS growth 1.25-1.5x AVXL's 25.00%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.